{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:50:13Z","timestamp":1790686213680,"version":"4.1.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been made in the management of CAT. The growing evidence base informing practice has led to the publication of a number of guidelines and guidance documents on the diagnosis and treatment of CAT. The goal of this review is to examine the latest versions of evidence-based guidelines, highlighting the differences and similarities in their methodology, their disease-specific content, and recommendations for management. Our analysis shows that for most clinical topics, the different guidelines provide roughly similar management advice. However, there are a number of important clinical topics in CAT that are not currently covered by the existing guidelines. We think inclusion of these topics in future versions of the guidelines will facilitate ongoing efforts to optimize the care of patients with CAT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>Cancer-associated thrombosis (CAT) is a common complication in patients with cancer. This review examines the differences and similarities of the current CAT guidelines methods and recommendations. Current guidelines largely agree on many aspects of CAT management. However, there are a number of topics in CAT that are not currently included in guidelines where evidence-based guidance would be very helpful for clinicians. Coverage of these topics in future guidelines is encouraged to optimize clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/onco.13596","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T09:07:47Z","timestamp":1607072867000},"page":"e24-e40","source":"Crossref","is-referenced-by-count":114,"title":["Update on Guidelines for the Management of Cancer-Associated Thrombosis"],"prefix":"10.1093","volume":"26","author":[{"given":"Michael B.","family":"Streiff","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Ali","family":"Abutalib","sequence":"additional","affiliation":[{"name":"Cancer Treatment Centers of America, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Farge","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de M\u00e9decine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), Universit\u00e9 de Paris, IRSL, Recherche clinique appliqu\u00e9e \u00e0 l'h\u00e9matologie, Paris, France"},{"name":"Department of Medicine, McGill University Health Center, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Murphy","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Cardiovascular Medicine Division at the Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Brigham and Womens Hospital and Dana-Farber Cancer Institute, Boston Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Cardiovascular Medicine Division at the Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Division of Hematology\/Oncology, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"2021122511450352100_onco13596-bib-0001","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/asheducation-2016.1.196","article-title":"Thrombosis in the setting of cancer","volume":"1","author":"Streiff","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122511450352100_onco13596-bib-0002","doi-asserted-by":"crossref","first-page":"838","DOI":"10.6004\/jnccn.2006.0071","article-title":"Venous thromboembolic disease. Clinical practice guidelines in oncology","volume":"4","author":"Wagman","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122511450352100_onco13596-bib-0003","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.critrevonc.2006.05.001","article-title":"Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM)","volume":"59","author":"Mandala","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122511450352100_onco13596-bib-0004","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","article-title":"American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer","volume":"25","author":"Lyman","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122511450352100_onco13596-bib-0005","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/annonc\/mdp052","article-title":"2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: Report from the working group","volume":"20","author":"Debourdeau","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122511450352100_onco13596-bib-0006","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021122511450352100_onco13596-bib-0007","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/jth.12683","article-title":"Subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in hospitalized medical cancer patients: Guidance from the SSC of the ISTH","volume":"12","author":"Di Nisio","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2021122511450352100_onco13596-bib-0008","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2021122511450352100_onco13596-bib-0009","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jth.12338","article-title":"Subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: Guidance from the SSC of the ISTH","volume":"11","author":"Carrier","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2021122511450352100_onco13596-bib-0010","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021122511450352100_onco13596-bib-0011","author":"NCCN","year":"2020"},{"key":"2021122511450352100_onco13596-bib-0012","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12094-019-02263-z","article-title":"SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)","volume":"22","author":"Munoz Martin","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"2021122511450352100_onco13596-bib-0013","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjmed.2013.09.015","article-title":"Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer","volume":"127","author":"Carrier","year":"2014","journal-title":"Am J Med"},{"key":"2021122511450352100_onco13596-bib-0014","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/annonc\/mdj068","article-title":"Risk factors for venous thromboembolic events in cancer patients","volume":"17","author":"Kroger","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122511450352100_onco13596-bib-0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2007-10-117051","article-title":"The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1,514 patients undergoing hematopoietic stem cell transplantation: Implications for VTE prevention","volume":"112","author":"Gerber","year":"2008","journal-title":"Blood"},{"key":"2021122511450352100_onco13596-bib-0016","first-page":"1263","article-title":"Prophylaxis against venous thromboembolism in patients with cancer","volume":"371","author":"Connors","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122511450352100_onco13596-bib-0017","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122511450352100_onco13596-bib-0018","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122511450352100_onco13596-bib-0019","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"2021122511450352100_onco13596-bib-0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122511450352100_onco13596-bib-0021","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122511450352100_onco13596-bib-0022","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and thrombotic complications of novel multiple myeloma therapies: A review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol"},{"key":"2021122511450352100_onco13596-bib-0023","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122511450352100_onco13596-bib-0024","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"2021122511450352100_onco13596-bib-0025","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/bjs.1800840817","article-title":"Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment","volume":"84","author":"ENOXACAN Study Group","year":"1997","journal-title":"Br J Surg"},{"key":"2021122511450352100_onco13596-bib-0026","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa012385","article-title":"Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer","volume":"346","author":"Bergqvist","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122511450352100_onco13596-bib-0027","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/j.1538-7836.2006.02153.x","article-title":"Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: A multicenter randomized open-label study","volume":"4","author":"Rasmussen","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2021122511450352100_onco13596-bib-0028","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122511450352100_onco13596-bib-0029","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa Inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122511450352100_onco13596-bib-0030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2021122511450352100_onco13596-bib-0031","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"2021122511450352100_onco13596-bib-0032","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: Guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2021122511450352100_onco13596-bib-0033","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"2021122511450352100_onco13596-bib-0034","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"2021122511450352100_onco13596-bib-0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.thromres.2019.08.021","article-title":"Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs","volume":"182","author":"Spyropoulos","year":"2019","journal-title":"Thromb Res"},{"key":"2021122511450352100_onco13596-bib-0036","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11239-016-1465-x","article-title":"Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)","volume":"43","author":"Hakeam","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"2021122511450352100_onco13596-bib-0037","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/eurheartj\/ehs408","article-title":"Acute management of bleeding in patients on novel oral anticoagulants","volume":"34","author":"Siegal","year":"2013","journal-title":"Eur Heart J"},{"key":"2021122511450352100_onco13596-bib-0038","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-12-21","article-title":"Venous thromboembolism in the elderly: Efficacy and safety of non-VKA oral anticoagulants","volume":"12","author":"Geldhof","year":"2014","journal-title":"Thromb J"},{"key":"2021122511450352100_onco13596-bib-0039","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122511450352100_onco13596-bib-0040","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"EINSTEIN-PE Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122511450352100_onco13596-bib-0041","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122511450352100_onco13596-bib-0042","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"key":"2021122511450352100_onco13596-bib-0043","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai-VTE Investigators","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122511450352100_onco13596-bib-0044","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122511450352100_onco13596-bib-0045","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2021122511450352100_onco13596-bib-0046","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2021122511450352100_onco13596-bib-0047","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"Grilz","year":"2018","journal-title":"Haematologica"},{"key":"2021122511450352100_onco13596-bib-0048","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.thromres.2010.10.001","article-title":"Arterial thrombosis in ambulatory cancer patients treated with chemotherapy","volume":"127","author":"Di Nisio","year":"2011","journal-title":"Thromb Res"},{"key":"2021122511450352100_onco13596-bib-0049","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjmed.2018.04.037","article-title":"RIETE Investigators. Arterial ischemic events are a major complication in cancer patients with venous thromboembolism","volume":"131","author":"Brenner","year":"2018","journal-title":"Am J Med"},{"key":"2021122511450352100_onco13596-bib-0050","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","article-title":"Thromboembolism in hospitalized neutropenic cancer patients","volume":"24","author":"Khorana","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122511450352100_onco13596-bib-0051","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2012.01.005","article-title":"Risk of haemorrhagic and ischaemic stroke in patients with cancer: A nationwide follow-up study from Sweden","volume":"48","author":"Zoller","year":"2012","journal-title":"Eur J Cancer"},{"key":"2021122511450352100_onco13596-bib-0052","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2011.09.015","article-title":"Risk of coronary heart disease in patients with cancer: A nationwide follow-up study from Sweden","volume":"48","author":"Zoller","year":"2012","journal-title":"Eur J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13596","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13596","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/1\/e24\/41923919\/oncolo_26_1_e24.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/1\/e24\/41923919\/oncolo_26_1_e24.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:46:46Z","timestamp":1640414806000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/1\/e24\/6445320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,4]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13596","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2020,12,4]]}}}